Skip to search formSkip to main contentSkip to account menu

bilastine

Known as: p-(2-(4-(1-(2-Ethoxyethyl)-2-benzimidazolyl)piperidino)ethyl)-alpha-methylhydratropic Acid 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Background Bilastine is a safe and effective commonly prescribed non-sedating H1-antihistamine approved for symptomatic treatment… 
2015
2015
Abstract Context: Bilastine is a new oral selective, non-sedating histamine H1 antagonist for the symptomatic treatment of… 
2014
2014
Background Allergic rhinitis is a very frequent disease. H1 antihistamines have been used for treatment of allergic rhinitis for… 
2014
2014
Background / Objective Prior use of “lymphocyte transformation test” (LTT) suggested that it was less often positive in Stevens… 
2014
2014
There is argument whether non-sedative properties of histamine H1-receptor antagonists (antihistamines) are determined by their… 
2012
2012
AbstractBackground and Objectives: The International Conference of Harmonisation (ICH) E14 guideline for thorough QT studies… 
Review
2012
Review
2012
As part of the bilastine development program, and as mandated by regulatory authorities, several studies were performed with oral… 
2011
2011
Bilastine is a potent inhibitor of the histamine H1 receptor. It was recently approved in 28 countries of the European Union for… 
Review
2011
Review
2011
Bilastine is a potent inhibitor of the histamine H1 receptor. It was recently approved in 28 countries of the European Union for… 
Review
2009